Stockscreener 앱 받기
47.69
1.21%
0.57
시간 외 거래:
48.50
0.81
+1.70%
전일 마감가:
$47.12
열려 있는:
$48.17
하루 거래량:
318.12K
Relative Volume:
0.53
시가총액:
$1.77B
수익:
$154.15M
순이익/손실:
$-33.58M
주가수익비율:
-49.68
EPS:
-0.96
순현금흐름:
$-20.74M
1주 성능:
+0.78%
1개월 성능:
+1.06%
6개월 성능:
+30.66%
1년 성능:
+49.45%
1일 변동 폭
$47.46
$49.20
1주일 범위
$46.00
$50.16
52주 변동 폭
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
명칭
Harrow Inc
전화
615.733.4731
주소
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
47.69 | 1.75B | 154.15M | -33.58M | -20.74M | -0.96 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | BTIG Research | Buy |
| 2025-06-10 | 개시 | William Blair | Outperform |
| 2025-02-06 | 개시 | H.C. Wainwright | Buy |
| 2024-12-04 | 재확인 | B. Riley Securities | Buy |
| 2024-04-11 | 개시 | Craig Hallum | Buy |
| 2022-09-08 | 재개 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-09-24 | 개시 | Aegis Capital | Buy |
| 2021-07-02 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Harrow Inc 주식(HROW)의 최신 뉴스
Can Harrow Inc. expand into new markets2025 Market Trends & Weekly Top Gainers Alerts - mfd.ru
Precision Trading with Harrow Health Inc. 8.625% Senior Notes Due 2026 (HROWL) Risk Zones - Stock Traders Daily
Loss Report: What are the future prospects of Harrow IncQuarterly Growth Report & Fast Gain Stock Tips - baoquankhu1.vn
Will Harrow Inc. stock attract more institutional investorsWeekly Trade Report & Weekly High Return Stock Forecasts - mfd.ru
Harrow, Inc. (HROW) Stock Analysis: A 48% Upside in the Promising Ophthalmic Pharmaceuticals Sector - DirectorsTalk Interviews
Is Harrow’s (HROW) Reaffirmed 2025 Guidance Quietly Redefining Its Ophthalmic Growth Strategy? - simplywall.st
Harrow Refocuses After ImprimisRx Exit As New CCO Takes Charge - Sahm
A Look At Harrow’s (HROW) Valuation As 2025 Guidance Is Reaffirmed And Regulatory Issues Clear - Yahoo Finance
New York State Common Retirement Fund Raises Stock Position in Harrow, Inc. $HROW - MarketBeat
B.Riley reiterates Buy rating on Harrow Health stock amid VEVYE growth - Investing.com
Harrow (NASDAQ:HROW) Downgraded by Zacks Research to "Hold" - MarketBeat
Growth Recap: Should I hold or sell Harrow Inc now2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - baoquankhu1.vn
Harrow Reaffirms FY2025 Revenue Growth Range Of 35% To 40%; Expands Sales Force - Nasdaq
Harrow Stock (+9.7%): Commercial Expansion Ignites Institutional Buying - Trefis
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? - Nasdaq
Rival quits California market; OSRX steps in to keep eye meds flowing - stocktitan.net
How Harrow Health Inc. (HROW) Affects Rotational Strategy Timing - Stock Traders Daily
Harrow on track to double sales force, expand product reach By Investing.com - Investing.com Nigeria
OSRX Continues Support in California Market After Competitor Exit - Intellectia AI
Harrow (NASDAQ:HROW) Shares Gap UpShould You Buy? - MarketBeat
Harrow on track to double sales force, expand product reach - Investing.com
(HROW) Harrow Expects 2025 Revenue Range $270M$280M, vs. FactSet Est of $273.4M - marketscreener.com
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth - marketscreener.com
Is Harrow Inc. attractive for institutional investors2025 Winners & Losers & Verified Momentum Stock Alerts - Mfd.ru
Harrow Becomes Oversold (HROW) - Nasdaq
Can Harrow Inc. be recession proofJuly 2025 Rallies & Daily Volume Surge Signals - mfd.ru
Risk Report: Is PMTV stock showing strong momentum2025 Price Targets & Low Volatility Stock Recommendations - baoquankhu1.vn
109,421 Shares in Harrow, Inc. $HROW Acquired by Blackhawk Capital Partners LLC - MarketBeat
Harrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update (NASDAQ:HROW) - Seeking Alpha
Harrow (NASDAQ:HROW) Shares Down 4.4%Time to Sell? - MarketBeat
Market Trends: Can Harrow Inc expand into new marketsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Pharma News: Can Harrow Inc. be recession proofTrade Risk Assessment & Weekly High Return Stock Forecasts - baoquankhu1.vn
Investment Recap: Can OptimizeRx Corporation weather a recessionQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) - Yahoo Finance
Assessing Harrow (HROW) Valuation After Its Shift To An Integrated U.S. Eye Care Pharma Platform - Sahm
LJI Wealth Management LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
Opaleye management sells $711,814 worth of Harrow shares - MSN
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
Harrow, Inc. (NASDAQ:HROW) Could Be Less Than A Year Away From Profitability - 富途资讯
Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength - sharewise.com
Harrow, Inc. (HROW): A Bull Case Theory - Finviz
Zacks Research Upgrades Harrow (NASDAQ:HROW) to "Strong-Buy" - MarketBeat
Gap Down: Can Harrow Inc maintain sales growthBull Run & Safe Capital Allocation Plans - baoquankhu1.vn
Harrow: Flirting With Missing 2025 Revised Guidance (NASDAQ:HROW) - Seeking Alpha
Value Recap: Will Harrow Inc benefit from geopolitical trendsWeekly Trend Summary & Weekly Momentum Stock Picks - baoquankhu1.vn
Responsive Playbooks and the HROW Inflection - Stock Traders Daily
Harrow Inc (HROW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Harrow Inc 주식 (HROW) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
1.19%
0.83%
자본화:
|
볼륨(24시간):